Formation by the endothelium of prostacyclin, nitric oxide and endothelin.
Prostacyclin and nitric oxide (NO) are two labile vasorelaxant and anti-aggregatory substances which are released by receptor activation and in response to shear forces acting on endothelial cells, whereas the potent constrictor peptide, endothelin-1 (ET-1) is probably slowly released and exerts long-term control over the cardiovascular system. This review deals with the synthesis, release and pharmacological actions of prostacyclin, NO and ET-1, as well as the diseases which might result from their under- or over-production.
Vane
J R
JR
William Harvey Research Institute, St Bartholomew's Hospital Medical College, London, UK.
Botting
R M
RM
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D016232:Endothelins / Q000096:biosynthesis*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D014652:Vascular Diseases / Q000188:drug therapy / Q000209:etiology
D016232:Endothelins; D009569:Nitric Oxide; D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin